

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 7,214,690 B2
APPLICATION NO. : 10/080503
DATED : May 8, 2007
INVENTOR(S) : Higuchi et al.

Page 1 of 11

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:


IN THE TITLE PAGES:

In Item [56] References Cited, in OTHER PUBLICATIONS:


in Venturoli et al., please replace "Prospectiove" with --Prospective--

IN THE SPECIFICATION:

At column 5, line 20, please replace structure




with the following structure: --




At column 9, line 34, please replace "A R⁹" with --R⁹--

At column 31, line 56-67, please replace structure



with the following structure: --



UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 7,214,690 B2
APPLICATION NO. : 10/080503
DATED : May 8, 2007
INVENTOR(S) : Higuchi et al.


Page 2 of 11

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

IN THE CLAIMS:

Column 79, line 40 thru Column 81, line 37 (Claim 1) should read
Please replace Claims 1, 10, 24, 40, 57, and 58 with the following Claims:

1. A compound having the formula:



wherein:

R¹ is selected from the group consisting of hydrogen, F, Cl, Br, I, NO₂, OR⁹, NR¹⁰R¹¹, S(O)_nR⁹, optionally substituted C₁–C₈ alkyl, optionally substituted C₁–C₈ haloalkyl, optionally substituted C₁–C₈ heteroalkyl, optionally substituted C₃–C₈ cycloalkyl, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heteroaryl, optionally substituted C₂–C₈ alkynyl and optionally substituted C₂–C₈ alkenyl;

R² is selected from the group consisting of hydrogen, F, Cl, Br, I, CF₃, CF₂Cl, CF₂H, CFH₂, CF₂OR⁹, CH₂OR⁹, OR⁹, S(O)_nR⁹, NR¹⁰R¹¹, optionally substituted C₁–C₈ alkyl, optionally substituted C₁–C₈ haloalkyl, optionally substituted C₁–C₈ heteroalkyl, optionally substituted C₃–C₈ cycloalkyl, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heteroaryl, optionally substituted C₂–C₈ alkynyl and optionally substituted C₂–C₈ alkenyl;

R³ and R⁴ each independently is selected from the group consisting of hydrogen, OR⁹, S(O)_nR⁹, NR¹⁰R¹¹, C(Y)OR¹¹, CNR¹⁰R¹¹, optionally substituted C₁–C₈ alkyl, optionally substituted C₁–C₈ haloalkyl, optionally substituted C₁–C₈ heteroalkyl, optionally substituted C₃–C₈ cycloalkyl, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heteroaryl, optionally substituted C₂–C₈ alkynyl and optionally substituted C₂–C₈ alkenyl;

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 7,214,690 B2
APPLICATION NO. : 10/080503
DATED : May 8, 2007
INVENTOR(S) : Higuchi et al.

Page 3 of 11

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

R^5 and R^6 each independently is selected from the group consisting of hydrogen, CF_3 , CF_2Cl , CF_2H , CFH_2 , optionally substituted C_1-C_8 alkyl, optionally substituted C_1-C_8 haloalkyl, optionally substituted C_1-C_8 heteroalkyl, optionally substituted C_3-C_8 cycloalkyl, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heteroaryl, optionally substituted C_2-C_8 alkynyl and optionally substituted C_2-C_8 alkenyl;

R^7 is selected from the group consisting of hydrogen, F, Cl, Br, I, optionally substituted C_1-C_8 alkyl, optionally substituted C_1-C_8 haloalkyl, optionally substituted C_1-C_8 heteroalkyl, optionally substituted aryl, optionally substituted heteroaryl, OR^9 , $S(O)_nR^9$, $NR^{10}R^{11}$, $C(Y)OR^{11}$ and $C(Y)NR^{10}R^{11}$;

R^8 is selected from the group consisting of hydrogen, F, Cl, Br, I, optionally substituted C_1-C_8 alkyl, optionally substituted C_1-C_8 haloalkyl, optionally substituted C_1-C_8 heteroalkyl, optionally substituted aryl, optionally substituted heteroaryl, OR^9 , $S(O)_nR^9$, $NR^{10}R^{11}$, $C(Y)OR^{11}$ and $C(Y)NR^{10}R^{11}$;

R^9 is selected from the group consisting of hydrogen, optionally substituted C_1-C_8 alkyl, optionally substituted C_1-C_8 haloalkyl, optionally substituted C_1-C_8 heteroalkyl, optionally substituted aryl, optionally substituted heteroaryl, and optionally substituted arylalkyl;

R^{10} is selected from the group consisting of hydrogen, optionally substituted C_1-C_8 alkyl, optionally substituted C_1-C_8 haloalkyl, optionally substituted C_1-C_8 heteroalkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted arylalkyl, CO_2R^{12} , $C(O)R^{12}$, SO_2R^{12} and $S(O)R^{12}$;

R^{11} and R^{12} each independently is selected from the group consisting of hydrogen, optionally substituted C_1-C_8 alkyl, optionally substituted C_1-C_8 haloalkyl, optionally substituted C_1-C_8 heteroalkyl, optionally substituted aryl, optionally substituted heteroaryl and optionally substituted arylalkyl;

R^{13} is selected from the group consisting of optionally substituted C_1-C_8 alkyl, optionally substituted C_1-C_8 haloalkyl, optionally substituted C_1-C_8 heteroalkyl, optionally substituted C_2-C_8 alkenyl, optionally substituted C_2-C_8 alkynyl, optionally substituted C_3-C_8 cycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted arylalkyl and optionally substituted heteroarylalkyl;

m is selected from the group consisting of 0, 1 and 2;

n is selected from the group consisting of 0, 1 and 2;

W is selected from the group consisting of NH, $N\{R^{13}\}$, $N\{C(Y)R^{11}\}$ and $N\{SO_2R^{11}\}$;

X is O;

Z is selected from the group consisting of NH, $N\{R^{11}\}$, $N\{C(Y)R^{11}\}$, $N\{SO_2R^{12}\}$ and $N\{S(O)R^{12}\}$; and

Y is O;

and pharmaceutically acceptable salts thereof; wherein:

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 7,214,690 B2
APPLICATION NO. : 10/080503
DATED : May 8, 2007
INVENTOR(S) : Higuchi et al.

Page 4 of 11

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

the substituents of an optionally substituted group comprise one or more substituents independently selected from among alkyl, alkenyl, alkynyl, heteroalkyl, haloalkyl, haloalkenyl, haloalkynyl, cycloalkyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl, alkoxy, aryloxy, haloalkoxy, amino, alkylamino, dialkylamino, alkylthio, arylthio, heteroarylthio, oxo, carboxyester, carboxamido, acyloxy, hydrogen, F, Cl, Br, I, CN, NO₂, NH₂, N₃, NHCH₃, N(CH₃)₂, SH, SCH₃, OH, OCH₃, OCF₃, CH₃, CF₃, C(O)CH₃, CO₂CH₃, CO₂H, C(O)NH₂, OR⁹, SR⁹, NR¹⁰R¹¹, CF₂CF₃, CH₂CH₂F and CH₂CF₃.

Column 82, lines 6-58, Claim 10 should read

10. The compound of claim 1, wherein:

R¹ is selected from the group consisting of hydrogen, F, Cl, Br, I, NO₂, OR⁹, NR¹⁰R¹¹, S(O)_nR⁹, C₁-C₈ alkyl, C₁-C₈ haloalkyl, C₁-C₈ heteroalkyl, C₃-C₈ cycloalkyl, aryl, arylalkyl, heteroaryl, C₂-C₈ alkynyl and C₂-C₈ alkenyl;

R² is selected from the group consisting of hydrogen, F, Cl, Br, I, CF₃, CF₂Cl, CF₂H, CFH₂, CF₂OR⁹, CH₂OR⁹, OR⁹, S(O)_nR⁹, NR¹⁰R¹¹, C₁-C₈ alkyl, C₁-C₈ haloalkyl, C₁-C₈ heteroalkyl, C₃-C₈ cycloalkyl, aryl, arylalkyl, heteroaryl, C₂-C₈ alkynyl and C₂-C₈ alkenyl;

R³ and R⁴ each independently is selected from the group consisting of hydrogen, OR⁹, S(O)_nR⁹, NR¹⁰R¹¹, C(Y)OR¹¹, C(Y)NR¹⁰R¹¹, C₁-C₈ alkyl, C₁-C₈ haloalkyl, C₁-C₈ heteroalkyl, C₃-C₈ cycloalkyl, aryl, arylalkyl, heteroaryl, C₂-C₈ alkynyl and C₂-C₈ alkenyl;

R⁵ and R⁶ each independently is selected from the group consisting of hydrogen, CF₃, CF₂Cl, CF₂H, CFH₂, C₁-C₈ alkyl, C₁-C₈ haloalkyl, C₁-C₈ heteroalkyl, C₃-C₈ cycloalkyl, aryl, arylalkyl, heteroaryl, C₂-C₈ alkynyl and C₂-C₈ alkenyl;

R⁷ is selected from the group consisting of hydrogen, F, Cl, Br, I, C₁-C₈ alkyl, C₁-C₈ haloalkyl, C₁-C₈ heteroalkyl, aryl, heteroaryl, OR⁹, S(O)_nR⁹, NR¹⁰R¹¹, C(Y)OR¹¹ and C(Y)NR¹⁰R¹¹;

R⁸ is selected from the group consisting of hydrogen, F, Cl, Br, I, C₁-C₈ alkyl, C₁-C₈ haloalkyl, C₁-C₈ heteroalkyl, aryl, heteroaryl, OR⁹, S(O)_nR⁹, NR¹⁰R¹¹, C(Y)OR¹¹ and C(Y)NR¹⁰R¹¹;

R⁹ is selected from the group consisting of hydrogen, C₁-C₈ alkyl, C₁-C₈ haloalkyl, C₁-C₈ heteroalkyl, aryl, heteroaryl and arylalkyl;

R¹⁰ is selected from the group consisting of hydrogen, C₁-C₈ alkyl, C₁-C₈ haloalkyl, C₁-C₈ heteroalkyl, aryl, heteroaryl, arylalkyl, CO₂R¹², C(O)R¹², SO₂R¹² and S(O)R¹²;

R¹¹ and R¹² each independently is selected from the group consisting of hydrogen, C₁-C₈ alkyl, C₁-C₈ haloalkyl, C₁-C₈ heteroalkyl, aryl, heteroaryl, arylalkyl;

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

Page 5 of 11

R¹³ is selected from the group consisting of C₁–C₈ alkyl, C₁–C₈ haloalkyl, C₁–C₈ heteroalkyl, C₂–C₈ alkenyl, C₂–C₈ alkynyl, C₃–C₈ cycloalkyl, aryl, heteroaryl, arylalkyl and heteroarylalkyl;

n is selected from the group consisting of 0, 1 and 2;

$$N\{SO_2R^{11}\};$$


Z is selected from the group consisting of NH, N{R¹¹}, N{C(Y)R¹¹},

$$\text{N}\{\text{SO}_2\text{R}^{12}\} \text{ and } \text{N}\{\text{S}(\text{O})\text{R}^{12}\}; \text{ and}$$

and pharmaceutically acceptable salts thereof.

24. A compound according to claim 23, wherein R⁹ is selected from the group consisting of hydrogen and optionally substituted C₁–C₄ alkyl.

40. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of formula:



R¹ is selected from the group consisting of hydrogen, F, Cl, Br, I, NO₂, OR⁹, NR¹⁰R¹¹, S(O)_nR⁹, optionally substituted C₁–C₈ alkyl, optionally substituted C₁–C₈ haloalkyl, optionally substituted C₁–C₈ heteroalkyl, optionally substituted C₃–C₈ cycloalkyl, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heteroaryl, optionally substituted C₂–C₈ alkynyl and optionally substituted C₂–C₈ alkenyl;

R² is selected from the group consisting of hydrogen, F, Cl, Br, I, CF₃, CF₂Cl, CF₂H, CFH₂, CF₂OR⁹, CH₂OR⁹, OR⁹, S(O)_nR⁹, NR¹⁰R¹¹, optionally substituted C₁–C₈ alkyl, optionally substituted C₁–C₈ haloalkyl, optionally substituted C₁–C₈ heteroalkyl, optionally substituted C₃–C₈ cycloalkyl, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heteroaryl, optionally substituted C₂–C₈ alkynyl and optionally substituted C₇–C₈ alkenyl;

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 7,214,690 B2
APPLICATION NO. : 10/080503
DATED : May 8, 2007
INVENTOR(S) : Higuchi et al.

Page 6 of 11

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

R^3 and R^4 each independently is selected from the group consisting of hydrogen, OR^9 , $S(O)_nR^9$, $NR^{10}R^{11}$, $C(Y)OR^{11}$, $C(Y)NR^{10}R^{11}$, optionally substituted C_1-C_8 alkyl, optionally substituted C_1-C_8 haloalkyl, optionally substituted C_1-C_8 heteroalkyl, optionally substituted C_3-C_8 cycloalkyl, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heteroaryl, optionally substituted C_2-C_8 alkynyl and optionally substituted C_2-C_8 alkenyl;

R^5 and R^6 each independently are selected from the group consisting of hydrogen, CF_3 , CF_2Cl , CF_2H , CFH_2 , optionally substituted C_1-C_8 alkyl, optionally substituted C_1-C_8 haloalkyl, optionally substituted C_1-C_8 heteroalkyl, optionally substituted C_3-C_8 cycloalkyl, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heteroaryl, optionally substituted C_2-C_8 alkynyl and optionally substituted C_2-C_8 alkenyl;

R^7 is selected from the group consisting of hydrogen, F, Cl, Br, I, optionally substituted C_1-C_8 alkyl, optionally substituted C_1-C_8 haloalkyl, optionally substituted C_1-C_8 heteroalkyl, optionally substituted aryl, optionally substituted heteroaryl, OR^9 , $S(O)_nR^9$, $NR^{10}R^{11}$, $C(Y)OR^{11}$ and $C(Y)NR^{10}R^{11}$;

R^8 is selected from the group consisting of hydrogen, F, Cl, Br, I, optionally substituted C_1-C_8 alkyl, optionally substituted C_1-C_8 haloalkyl, optionally substituted C_1-C_8 heteroalkyl, optionally substituted aryl, optionally substituted heteroaryl, OR^9 , $S(O)_nR^9$, $NR^{10}R^{11}$, $C(Y)OR^{11}$ and $C(Y)NR^{10}R^{11}$;

R^9 is selected from the group consisting of hydrogen, optionally substituted C_1-C_8 alkyl, optionally substituted C_1-C_8 haloalkyl, optionally substituted C_1-C_8 heteroalkyl, optionally substituted aryl, optionally substituted heteroaryl and optionally substituted arylalkyl;

R^{10} is selected from the group consisting of hydrogen, optionally substituted C_1-C_8 alkyl, optionally substituted C_1-C_8 haloalkyl, optionally substituted C_1-C_8 heteroalkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted arylalkyl, CO_2R^{12} , $C(O)R^{12}$, SO_2R^{12} and $S(O)R^{12}$;

R^{11} and R^{12} each independently is selected from the group consisting of hydrogen, optionally substituted C_1-C_8 alkyl, optionally substituted C_1-C_8 haloalkyl, optionally substituted C_1-C_8 heteroalkyl, optionally substituted aryl, optionally substituted heteroaryl and optionally substituted arylalkyl;

R^{13} is selected from the group consisting of optionally substituted C_1-C_8 alkyl, optionally substituted C_1-C_8 haloalkyl, optionally substituted C_1-C_8 heteroalkyl, optionally substituted C_2-C_8 alkenyl, optionally substituted C_2-C_8 alkynyl, optionally substituted C_3-C_8 cycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted arylalkyl and optionally substituted heteroarylalkyl;

m is 1;

n is selected from the group consisting of 0, 1 and 2;

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 7,214,690 B2
APPLICATION NO. : 10/080503
DATED : May 8, 2007
INVENTOR(S) : Higuchi et al.

Page 7 of 11

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

W is selected from the group consisting of NH, N{R¹³}, N{C(Y)R¹¹} and N{SO₂R¹¹};

X is O;

Z is selected from the group consisting of NH, N{R¹¹}, N{C(Y)R¹¹}, N{SO₂R¹²} and N{S(O)R¹²}; and

Y is O;

and pharmaceutically acceptable salts thereof; wherein:

the substituents of an optionally substituted group comprise one or more substituents independently selected from among alkyl, alkenyl, alkynyl, heteroalkyl, haloalkyl, haloalkenyl, haloalkynyl, cycloalkyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl, alkoxy, aryloxy, haloalkoxy, amino, alkylamino, dialkylamino, alkythio, arylthio, heteroarylthio, oxo, carboxyester, carboxamido, acyloxy, hydrogen, F, Cl, Br, I, CN, NO₂, NH₂, N₃, NHCH₃, N(CH₃)₂, SH, SCH₃, OH, OCH₃, OCF₃, CH₃, CF₃, C(O)CH₃, CO₂CH₃, CO₂H, C(O)NH₂, OR⁹, SR⁹, NR¹⁰R¹¹, CF₂CF₃, CH₂CH₂F and CH₂CF₃.

Column 88, line 27 thru Column 90, line 35, Claim 57 should read

57. A compound selected from the group consisting of:

(3R)-2,3,4,7-Tetrahydro-3-methyl-10-(trifluoromethyl)-8H-[1,4]oxazino[2,3-f]-quinolin-8-one;

(3R)-2,3,4,7-Tetrahydro-3,4-dimethyl-10-(trifluoromethyl)-8H-[1,4]oxazino[2,3-f]-quinolin-8-one;

(3R)-4-Ethyl-2,3,4,7-tetrahydro-3-methyl-10-(trifluoromethyl)-8H-[1,4]oxazino[2,3-f]-quinolin-8-one;

(3R)-2,3,4,7-Tetrahydro-3-methyl-4-(2,2,2-trifluoroethyl)-10-(trifluoromethyl)-8H-[1,4]oxazino[2,3-f]quinolin-8-one;

(3R)-2,3,4,7-Tetrahydro-3-methyl-4-propyl-10-(trifluoromethyl)-8H-[1,4]oxazino[2,3-f]-quinolin-8-one;

(3R)-4-Allyl-2,3,4,7-tetrahydro-3-methyl-10-(trifluoromethyl)-8H-[1,4]oxazino[2,3-f]-quinolin-8-one;

(3R)-3-Ethyl-2,3,4,7-tetrahydro-10-(trifluoromethyl)-8H-[1,4]oxazino[2,3-f]quinolin-8-one;

(3R)-3-Ethyl-2,3,4,7-tetrahydro-4-methyl-10-(trifluoromethyl)-8H-[1,4]oxazino[2,3-f]-quinolin-8-one;

(3R)-3,4-Diethyl-2,3,4,7-tetrahydro-10-(trifluoromethyl)-8H-[1,4]oxazino[2,3-f]-quinolin-8-one;

(3R)-3-Ethyl-2,3,4,7-tetrahydro-4-(2,2,2-trifluoroethyl)-10-(trifluoromethyl)-8H-[1,4]oxazino[2,3-f]quinolin-8-one;

(3R)-4-(2-Chloro-2,2-difluoroethyl)-3-ethyl-2,3,4,7-tetrahydro-10-(trifluoromethyl)-8H-[1,4]oxazino[2,3-f]quinolin-8-one;

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 7,214,690 B2
APPLICATION NO. : 10/080503
DATED : May 8, 2007
INVENTOR(S) : Higuchi et al.

Page 8 of 11

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

(3R)-4-(2,2-Difluoroethyl)-3-ethyl-2,3,4,7-tetrahydro-10-(trifluoromethyl)-8H-[1,4]oxazino[2,3-f]quinolin-8-one;
(3R)-3-Ethyl-2,3,4,7-tetrahydro-4-propyl-10-(trifluoromethyl)-8H-[1,4]oxazino[2,3-f]quinolin-8-one;
(3R)-4-Allyl-3-ethyl-2,3,4,7-tetrahydro-10-(trifluoromethyl)-8H-[1,4]oxazino[2,3-f]quinolin-8-one;
(3R)-3-Ethyl-2,3,4,7-tetrahydro-4-isobutyl-10-(trifluoromethyl)-8H-[1,4]oxazino[2,3-f]quinolin-8-one;
(3R/S)-2,3,4,7-Tetrahydro-3-propyl-10-(trifluoromethyl)-8H-[1,4]oxazino[2,3-f]quinolin-8-one;
(3R/S)-2,3,4,7-Tetrahydro-4-methyl-3-propyl-10-(trifluoromethyl)-8H-[1,4]oxazino-[2,3-f]quinolin-8-one;
(3R/S)-4-Ethyl-2,3,4,7-tetrahydro-3-propyl-4-(2,2,2-trifluoroethyl)-10-(trifluoromethyl)-8H-[1,4]oxazino[2,3-f]quinolin-8-one;
(3R/S)-2,3,4,7-Tetrahydro-3-propyl-4-(2,2,2-trifluoroethyl)-10-(trifluoromethyl)-8H-[1,4]oxazino[2,3-f]quinolin-8-one;
(3R)-2,3,4,7-Tetrahydro-3-isopropyl-10-(trifluoromethyl)-8H-[1,4]oxazino[2,3-f]quinolin-8-one;
(3R)-2,3,4,7-Tetrahydro-3-isopropyl-4-methyl-10-(trifluoromethyl)-8H-[1,4]oxazino-[2,3-f]quinolin-8-one;
(3R)-4-Ethyl-2,3,4,7-tetrahydro-3-isopropyl-10-(trifluoromethyl)-8H-[1,4]oxazino-[2,3-f]quinolin-8-one;
(3R)-2,3,4,7-Tetrahydro-3-isopropyl-4-(2,2,2-trifluoroethyl)-10-(trifluoromethyl)-8H-[1,4]oxazino[2,3-f]quinolin-8-one;
(3R)-4-(2-Chloro-2,2-difluoroethyl)-2,3,4,7-tetrahydro-3-isopropyl-10-(trifluoromethyl)-8H-[1,4]oxazino[2,3-f]quinolin-8-one;
(3R)-4-(2,2-Difluoroethyl)-2,3,4,7-tetrahydro-3-isopropyl-10-(trifluoromethyl)-8H-[1,4]oxazino[2,3-f]quinolin-8-one;
(3R)-4-Allyl-2,3,4,7-tetrahydro-3-isopropyl-10-(trifluoromethyl)-8H-[1,4]oxazino-[2,3-f]quinolin-8-one;
(3R)-2,3,4,7-Tetrahydro-3-phenyl-10-(trifluoromethyl)-8H-[1,4]oxazino[2,3-f]quinolin-8-one;
(3R)-2,3,4,7-Tetrahydro-3-phenyl-4-(2,2,2-trifluoroethyl)-10-(trifluoromethyl)-8H-[1,4]oxazino[2,3-f]quinolin-8-one;
(3R)-4-Cyclopropylmethyl-2,3,4,7-tetrahydro-3-phenyl-10-(trifluoromethyl)-8H-[1,4]oxazino[2,3-f]quinolin-8-one;
(3R)-3-Benzyl-2,3,4,7-tetrahydro-4-(2,2,2-trifluoroethyl)-10-(trifluoromethyl)-8H-[1,4]oxazino[2,3-f]quinolin-8-one;

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 7,214,690 B2
APPLICATION NO. : 10/080503
DATED : May 8, 2007
INVENTOR(S) : Higuchi et al.

Page 9 of 11

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

2,3,4,7-Tetrahydro-10-(trifluoromethyl)-8H-[1,4]oxazino[2,3-f]quinolin-8-one;
2,3,4,7-tetrahydro-4-(2,2,2-trifluoroethyl)-10-(trifluoromethyl)-8H-[1,4]oxazino
[2,3-f]quinolin-8-one;
(7aR,10aS)-7,7a,8,9,10,10a-Hexahydro-1-(trifluoromethyl)
-7-(2,2,2-trifluoroethyl)-4H-cyclopenta[5,6][1,4]oxazino[2,3-f]quinolin-3-one;
(7aR,10aS)-7-Ethyl-7,7a,8,9,10,10a-hexahydro-1-(trifluoromethyl)
-4H-cyclopenta-[5,6][1,4]oxazino[2,3-f]quinolin-3-one;
(7aR,10aS)-7,7a,8,9,10,10a-Hexahydro-3-isopropoxy-1-(trifluoromethyl)
-7-(2,2,2-trifluoroethyl)-4H-cyclopenta[5,6][1,4]oxazino[2,3-f]quinolin-3-one;
(±)-(2S,3R)-2,3,4,7-Tetrahydro-2,3-dimethyl-4-(2,2,2-trifluoroethyl)
-10-(trifluoromethyl)-8H-[1,4]oxazino[2,3-f]quinolin-8-one;
(6aR)-6a,7,8,9-Tetrahydro-4-(trifluoromethyl)-1H,6H-pyrrolo[1',2':4,5][1,4]
-oxazino[2,3-f]quinolin-2-one;
2,3,4,7-Tetrahydro-2,2,4-trimethyl-10-(trifluoromethyl)-8H-[1,4]oxazino
[2,3-f]-quinolin-8-one;
(3R)-8-Chloro-3-ethyl-3,4-dihydro-8-isopropoxy-4-(2,2,2-trifluoroethyl)
-10-(trifluoromethyl)-2H-[1,4]oxazino[2,3-f]quinoline;
(3R)-3-Ethyl-3,4-dihydro-8-isopropoxy-8-methoxy-4-(2,2,2-trifluoroethyl)
-10-(trifluoromethyl)-2H-[1,4]oxazino[2,3-f]quinoline;
(±)-2,3,4,7-Tetrahydro-4-(2,2,2-trifluoroethyl)-3,10-bis(trifluoromethyl)
-8H-[1,4]oxazino[2,3-f]quinolin-8-one;
(-)-2,3,4,7-Tetrahydro-4-(2,2,2-trifluoroethyl)-3,10-bis(trifluoromethyl)
-8H-[1,4]oxazino[2,3-f]quinolin-8-one;
(+)-2,3,4,7-Tetrahydro-4-(2,2,2-trifluoroethyl)-3,10-bis(trifluoromethyl)
-8H-[1,4]oxazino[2,3-f]quinolin-8-one;
(±)-2,3,4,7-Tetrahydro-3-(2,2,2-trifluoroethyl)-10-(trifluoromethyl)-8H-[1,4]
oxazino[2,3-f]quinolin-8-one;
(±)-2,3,4,7-Tetrahydro-4-methyl-3-(2,2,2-trifluoroethyl)-10-(trifluoromethyl)
-8H-[1,4]oxazino[2,3-f]quinolin-8-one;
(±)-4-Ethyl-2,3,4,7-tetrahydro-3-(2,2,2-trifluoroethyl)-10-(trifluoromethyl)
-8H-[1,4]oxazino[2,3-f]quinolin-8-one;
(±)-2,3,4,7-Tetrahydro-3,4-bis(2,2,2-trifluoroethyl)-10-(trifluoromethyl)
-8H-[1,4]oxazino[2,3-f]quinolin-8-one;
(-)-2,3,4,7-Tetrahydro-3,4-bis(2,2,2-trifluoroethyl)-10-(trifluoromethyl)
-8H-[1,4]oxazino[2,3-f]quinolin-8-one;
(+)-2,3,4,7-Tetrahydro-3,4-bis(2,2,2-trifluoroethyl)-10-(trifluoromethyl)
-8H-[1,4]oxazino[2,3-f]quinolin-8-one;

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 7,214,690 B2
APPLICATION NO. : 10/080503
DATED : May 8, 2007
INVENTOR(S) : Higuchi et al.

Page 10 of 11

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

(±)-4-Cyclopropylmethyl-2,3,4,7-tetrahydro-3-(2,2,2-trifluoroethyl)-10-(trifluoromethyl)-8H-[1,4]oxazino[2,3-f]quinolin-8-one;
(3R)-4-Cyclopropylmethyl-3-ethyl-2,3,4,7-tetrahydro-10-(trifluoromethyl)-8H-[1,4]oxazino[2,3-f]quinolin-8-one;
(3R)-4-(2-Chloroethyl)-2,3,4,7-tetrahydro-3-isopropyl-10-(trifluoromethyl)-8H-[1,4]oxazino[2,3-f]quinolin-8-one;
(±)-2,3,4,7-Tetrahydro-2-methyl-4-(2,2,2-trifluoroethyl)-10-(trifluoromethyl)-8H-[1,4]oxazino[2,3-f]quinolin-8-one;
(3R)-3-Ethyl-4-(2-hydroxy-2-methylpropyl)-2,3,4,7-tetrahydro-10-(trifluoromethyl)-8H-[1,4]oxazino[2,3-f]quinolin-8-one; and
(3R)-2,3,4,7-Tetrahydro-3-isobutyl-4-(2,2,2-trifluoroethyl)-10-(trifluoromethyl)-8H-[1,4]oxazino[2,3-f]quinolin-8-one; and
pharmaceutically acceptable salts thereof.

Column 90, line 35 thru Column 92, line 4 Claim 58 should read

58. A compound selected from the group consisting of:
(3R)-2,3,4,7-Tetrahydro-3-methyl-4-(2,2,2-trifluoroethyl)-10-(trifluoromethyl)-8H-[1,4]oxazino[2,3-f]quinolin-8-one;
(3R)-3-Ethyl-2,3,4,7-tetrahydro-4-(2,2,2-trifluoroethyl)-10-(trifluoromethyl)-8H-[1,4]oxazino[2,3-f]quinolin-8-one;
(3R)-4-(2-Chloro-2,2-difluoroethyl)-3-ethyl-2,3,4,7-tetrahydro-10-(trifluoromethyl)-8H-[1,4]oxazino[2,3-f]quinolin-8-one;
(3R)-4-(2,2-Difluoroethyl)-3-ethyl-2,3,4,7-tetrahydro-10-(trifluoromethyl)-8H-[1,4]oxazino[2,3-f]quinolin-8-one;
(3R)-2,3,4,7-Tetrahydro-3-isopropyl-4-(2,2,2-trifluoroethyl)-10-(trifluoromethyl)-8H-[1,4]oxazino[2,3-f]quinolin-8-one;
(3R)-4-(2-Chloro-2,2-difluoroethyl)-2,3,4,7-tetrahydro-3-isopropyl-10-(trifluoromethyl)-8H-[1,4]oxazino[2,3-f]quinolin-8-one;
(3R)-4-(2,2-Difluoroethyl)-2,3,4,7-tetrahydro-3-isopropyl-10-(trifluoromethyl)-8H-[1,4]oxazino[2,3-f]quinolin-8-one;
(7aR,10aS)-7-Ethyl-7,7a,8,9,10,10a-hexahydro-1-(trifluoromethyl)-4H-cyclopenta[5,6][1,4]oxazino[2,3-f]quinolin-3-one;
(7aR,10aS)-7-7a,8,9,10,10a-Hexahydro-1-(trifluoromethyl)-7-(2,2,2-trifluoroethyl)-4H-cyclopenta[5,6][1,4]oxazino[2,3-f]quinolin-3-one;
(±)-(2S,3R)-2,3,4,7-Tetrahydro-2,3-dimethyl-4-(2,2,2-trifluoroethyl)-10-(trifluoromethyl)-8H-[1,4]oxazino[2,3-f]quinolin-8-one;
(±)-2,3,4,7-Tetrahydro-4-(2,2,2-trifluoroethyl)-3,10-bis(trifluoromethyl)-8H-[1,4]oxazino[2,3-f]quinolin-8-one;

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 7,214,690 B2
APPLICATION NO. : 10/080503
DATED : May 8, 2007
INVENTOR(S) : Higuchi et al.

Page 11 of 11

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

(-)-2,3,4,7-Tetrahydro-4-(2,2,2-trifluoroethyl)-3,10-bis(trifluoromethyl)
-8H-[1,4]oxazino[2,3-f]quinolin-8-one; and
(+)-2,3,4,7-Tetrahydro-4-(2,2,2-trifluoroethyl)-3,10-bis(trifluoromethyl)
-8H-[1,4]oxazino[2,3-f]quinolin-one; and
pharmaceutically acceptable salts thereof.

This certificate supersedes the Certificate of Correction issued June 17, 2008.

Signed and Sealed this

Twenty-second Day of July, 2008

A handwritten signature in black ink, appearing to read "Jon W. Dudas". The signature is stylized with a large, looped initial "J" and a distinct "D" at the end.

JON W. DUDAS
Director of the United States Patent and Trademark Office